Application of snase in preparation of medicine for treating inflammatory bowel disease

Abstract

The invention relates to the application of staphylococcal nuclease (SNase) in preparation of a medicament for preventing or treating inflammatory bowel disease. The object of the present invention isto provide a novel use of SNase in action of resisting inflammatory bowel disease. Results show that SNase can significantly alleviate colonic inflammation in C57BL / 6J mice, can better control the body weight, colon length, fecal occult blood and inflammatory infiltration of the C57BL / 6J mice, and significantly improve the survival rate of the C57BL / 6J mice. Therefore, the SNase can significantlyalleviate intestinal inflammation in the C57BL / 6J mice, and can be used for development of medicaments for prevention and treatment of inflammatory bowel diseases.

Description

technical field [0001] The invention relates to a nuclease SNase with anti-inflammatory bowel disease function, as well as derivatives containing the nuclease and similar pharmaceutical preparations. The invention relates to the related fields of pharmacy and medicine. Background technique [0002] Inflammatory bowel disease (IBD) is a group of chronic intestinal diseases of unknown etiology, including inflammatory bowel disease (Ulcerative Colitis, UC) and Crohn's disease (Crohn's disease, CD). It is common in western countries, and the prevalence in European and North American countries is as high as 120-200 / 100,000. It is a common disease in the digestive field. With the change of lifestyle and the improvement of living standards, the incidence of IBD in our country presents an increasing trend year by year, and has become a common disease of the digestive system and the main cause of chronic diarrhea and bloody stool in our country. There are differences in the location...

AI Technical Summary

Problems solved by technology

At present, the traditional drugs marketed for the treatment of IBD, such as aminosalicylic acids mainly include sulfasalazine, etc., but they cannot eradicate the disease, and there is a high recurrence rate, while glucocorticoids have many adverse reactions, Improper use can easily cause shock. At present, common biological agents include anti-TNF monoclonal antibodies such as infliximab, adalimumab, and cytokine inhibitors, but biological agents are expensive and have a certain degree of adverse reactions. There are not many preparations for treatment, and most of the administration methods are non-oral administration, and the patient's compliance is poor

Therefore, it shows that IBD is a complex autoimmune disease caused by multiple factors. Immunosuppression alone cannot achieve good results. Therefore, it is imperative to find new targets and study new treatments.

Images